These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
210 related items for PubMed ID: 20428808
1. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D. Oncol Rep; 2010 Jun; 23(6):1545-52. PubMed ID: 20428808 [Abstract] [Full Text] [Related]
2. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, Kozlowski J, Smith N, Kundu SD, Yang G, Raji AA, Javonovic B, Pins M, Lindholm P, Guo Y, Catalona WJ, Lee C. Clin Cancer Res; 2009 May 15; 15(10):3557-67. PubMed ID: 19447876 [Abstract] [Full Text] [Related]
4. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. J Urol; 2004 May 15; 171(5):1934-8. PubMed ID: 15076315 [Abstract] [Full Text] [Related]
5. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L, Fan JH, Wang XY, He DL. Acta Pharmacol Sin; 2009 Aug 15; 30(8):1162-8. PubMed ID: 19578386 [Abstract] [Full Text] [Related]
6. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Mol Carcinog; 2004 Jul 15; 40(3):143-9. PubMed ID: 15224346 [Abstract] [Full Text] [Related]
12. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Zi X, Zhang J, Agarwal R, Pollak M. Cancer Res; 2000 Oct 15; 60(20):5617-20. PubMed ID: 11059749 [Abstract] [Full Text] [Related]
13. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Mokhtari MJ, Motamed N, Shokrgozar MA. Cell Biol Int; 2008 Aug 15; 32(8):888-92. PubMed ID: 18538589 [Abstract] [Full Text] [Related]
14. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Zerbini LF, Wang Y, Cho JY, Libermann TA. Cancer Res; 2003 May 01; 63(9):2206-15. PubMed ID: 12727841 [Abstract] [Full Text] [Related]
15. Prostate cancer chemoprevention by silibinin: bench to bedside. Singh RP, Agarwal R. Mol Carcinog; 2006 Jun 01; 45(6):436-42. PubMed ID: 16637061 [Abstract] [Full Text] [Related]
16. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Liu H, Chen A, Guo F, Yuan L. Cancer Lett; 2010 Sep 01; 295(1):27-37. PubMed ID: 20207476 [Abstract] [Full Text] [Related]
17. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression. Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko VM. Carcinogenesis; 2006 Oct 01; 27(10):1980-90. PubMed ID: 16606632 [Abstract] [Full Text] [Related]
18. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, Guo P, Li L, Wang X, He D. Cell Signal; 2013 Dec 01; 25(12):2625-33. PubMed ID: 24012496 [Abstract] [Full Text] [Related]
20. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Prostate; 2002 Nov 01; 53(3):211-7. PubMed ID: 12386921 [Abstract] [Full Text] [Related] Page: [Next] [New Search]